Abstract: A pharmaceutical composition for preventing or treating muscle atrophy or sarcopenia including glucagon-like peptide-1 (GLP-1), a GLP-1 fragment, a GLP-1 secretion enhancer, a GLP-1 degradation inhibitor, a GLP-1 receptor (GLP-1R) agonist, or exendin-4, and a method of treating muscle atrophy or sarcopenia by using the pharmaceutical composition. When the pharmaceutical composition is administered to a subject having sarcopenia or muscle atrophy, reduced body weight, skeletal muscle mass, and grip strength, which are caused by sarcopenia or muscle atrophy, and expression levels of genes involved in muscle production may be restored to normal states. The composition may be widely applied to the development of effective therapeutic agents for sarcopenia or muscle atrophy.

Abstract: Provided are a pharmaceutical composition for preventing or treating muscle atrophy or sarcopenia including glucagon-like peptide-1 (GLP-1), a GLP-1 fragment, a GLP-1 secretion enhancer, a GLP-1 degradation inhibitor, a GLP-1 receptor (GLP-1R) agonist, or exendin-4, and a method of treating muscle atrophy or sarcopenia by using the pharmaceutical composition. When the pharmaceutical composition for preventing or treating muscle atrophy or sarcopenia provided in the present invention is administered to a subject having sarcopenia or muscle atrophy, reduced body weight, skeletal muscle mass, and grip strength, which are caused by sarcopenia or muscle atrophy, and expression levels of genes involved in muscle production may be restored to normal states, and therefore, the composition may be widely applied to the development of effective therapeutic agents for sarcopenia or muscle atrophy.

Abstract: A pharmaceutical composition for preventing or treating muscle atrophy or sarcopenia including glucagon-like peptide-1 (GLP-1), a GLP-1 fragment, a GLP-1 secretion enhancer, a GLP-1 degradation inhibitor, a GLP-1 receptor (GLP-1R) agonist, or exendin-4, and a method of treating muscle atrophy or sarcopenia by using the pharmaceutical composition. When the pharmaceutical composition is administered to a subject having sarcopenia or muscle atrophy, reduced body weight, skeletal muscle mass, and grip strength, which are caused by sarcopenia or muscle atrophy, and expression levels of genes involved in muscle production may be restored to normal states. The composition may be widely applied to the development of effective therapeutic agents for sarcopenia or muscle atrophy.

Abstract: Provided are a pharmaceutical composition for preventing or treating muscle atrophy or sarcopenia including glucagon-like peptide-1 (GLP-1), a GLP-1 fragment, a GLP-1 secretion enhancer, a GLP-1 degradation inhibitor, a GLP-1 receptor (GLP-1R) agonist, or exendin-4, and a method of treating muscle atrophy or sarcopenia by using the pharmaceutical composition. When the pharmaceutical composition for preventing or treating muscle atrophy or sarcopenia provided in the present invention is administered to a subject having sarcopenia or muscle atrophy, reduced body weight, skeletal muscle mass, and grip strength, which are caused by sarcopenia or muscle atrophy, and expression levels of genes involved in muscle production may be restored to normal states, and therefore, the composition may be widely applied to the development of effective therapeutic agents for sarcopenia or muscle atrophy.

Abstract: The present invention relates to a cDNA chip for screening and function analysis of swine genes and provides a cDNA chip comprising a probe to detect marker genes specifically expressed in the muscle and fat tissues of swine, in which the probe is capable of complementarily bind to the marker genes. Also, the present invention provides expression profiles of marker genes which are related to economic traits of swine by using the cDNA chip according to the present invention. Therefore, the cDNA chip according to the present invention can be used for the comparison of genetic expression according to swine breeds and tissues, genetic mutation screening, genetic polymorphism interpretation, development of new drugs for disease treatment and disease diagnosis, swine improvement.

Abstract: The present invention relates to screening of the expression profile of muscle specific genes according to the growing stages in swine and a functional cDNA chip using the same and provides expression files of the muscle specific genes specifically expressed according to the growing stages in the muscle and fat tissues of swine. Also, the present invention provides a functional cDNA chip for meat quality evaluation and screening of specific genes in swine prepared by integrating only the muscle specific genes screened as described above. Therefore, the functional cDNA chip can be used to evaluate of meat quality according to breeds of swine and to bring a high meat quality swine.

Abstract: The present invention relates to screening of the expression profile of fat specific genes according to the growing stages in swine and a functional cDNA chip using the same and provides expression files of the fat specific genes specifically expressed according to the growing stages in the muscle and fat tissues of swine. Also, the present invention provides a functional cDNA chip for meat quality evaluation and screening of specific genes in swine prepared by integrating only the fat specific genes screened as described above. Therefore, the functional cDNA chip can be used to evaluate of meat quality according to breeds of swine and to bring a high meat quality swine.